Mechanisms of superior ants-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells

Journal of Immunotherapy

Volumn 28, Issue 1, 2005, Pages 44-52

  Özdemir, Öner ^a,c   Ravindranath, Yaddanapudi ^a   Savaşan, Süreyya ^a,b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD3 PHA + interleukin 2; Flow cytometric cell mediated cytotoxicity assay; Interleukin 15; Interleukin 2; Lymphokine activated killer activity

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; MITOGENIC AGENT; MONOCLONAL ANTIBODY CD3; PERFORIN; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; GAMMA INTERFERON; GRANZYME; GZMB PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PORE FORMING CYTOTOXIC PROTEIN; SERINE PROTEINASE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL COUNT; CELL LINE; CELL PROLIFERATION; CELL STRAIN K 562; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DAUDI CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL; CYTOTOXICITY TEST; DRUG EFFECT; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; METABOLISM; MONONUCLEAR CELL; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; MEMBRANE GLYCOPROTEINS; PHYTOHEMAGGLUTININS; PORE FORMING CYTOTOXIC PROTEINS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11344264596     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200501000-00006     Document Type: Article

References (48)

1. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-1841.
2. Ohkawa T, Seki S, Dobashi H, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology. 2001;103:281-290.
3. + killer cells. Ann Hematol. 1997;74:51-56.
4. Nakajima F, Khanna A, Xu G, et al. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc Natl Acad Sci USA. 1994;91:7889-7893.
5. + T cells proliferation but is unable to drive cytokine production in the absence of TCR activation or IL-12/IL-4 stimulation in vitro. Eur J Immunol. 2002;32:341-347.
6. Munger W, Dejoy SQ, Jeyaseelan R, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol. 1995;165:289-293.
7. Wiebke EA, Custer MC, Rosenberg SA, et al. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex restricted effectors reveals differential effects on natural and lymphokine-activated killing. J Biol Response Mod. 1990;9:113-126.
8. Kobayashi H, Carrasquillo JA, Paik CH, et al. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res. 2000;60:3577-3583.
9. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
10. Campbell JD, Cook G, Robertson SE, et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol. 2001;167:553-561.
11. PoIi G, Bordignon C. Unplugging the T cell receptor. Nat Immunol. 2003;4:943-944.
12. Rubinstein MP, Kadima AN, Salem ML, et al. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol. 2002;169:4928-4935.
13. Umemura M, Nishimura H, Saito K, et al. Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette Guerin vaccination. Infect Immun. 2003;71:6045-6048.
14. Kishida T, Asada H, Itokawa Y, et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther. 2003;8:552-558.
15. Hasan MS, Kallas EG, Thomas EK, et al. Effects of interleukin-15 on in vitro human T cell proliferation and activation. J Interferon Cytokine Res. 2000;20:119-123.
16. Özdemir Ö, Buck S, Ravindranath Y, et al. Interleukin- 2 and interleukin-15 combination induces lymphokine-activated killer cells with higher perform and granzyme-B expression patterns and superior cytotoxic response against human leukemia cells. Blood. 2002;100:471a.
17. Ye W, Young JD, Liu CC. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell Immunol. 1996;174:54-62.
18. Borrione P, Montacchini L, Beggiato E, et al. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2. Leuk Lymphoma. 1996;21:325-330.
19. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol. 1991;147:729-737.
20. Andersson U, Sander B. Detection of individual interleukin 2-producing cells after anti-CD3 antibody activation. Immunol Lett. 1989;20:115-120.
21. Anderson PM, Ochoa AC, Ramsay NK, et al. Anti-CD 3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity. Blood. 1992;80:1846-1853.
22. Dunne J, Lynch S, O'Farrelly C, et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. 2001;167:3129-3138.
23. Özdemir Ö, Ravindranath Y, Savasan S. Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexin V/propidium iodide co-labeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry. 2003;56A:53-60.
24. Jong JL, Farner NL, Javorsky BR, et al. Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy. Clin Cancer Res. 1998;4:1287-1296.
25. Gesbert F, Delespine-Carmagnat M, Bertoglio J. Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol. 1998;18:307-320.
26. Jang GC, Kim HY, Ahn SY, et al. Raised serum interleukin 15 levels in Kawasaki disease. Ann Rheum Dis. 2003;62:264-266.
27. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 2002;13:169-183.
28. Garovoy MR, Carpenter CB. Lymphocyte-mediated cytotoxicity. In: Rose NR, Friedman H, eds. Manual of Clinical Immunology. 2nd ed. Washington, DC: American Society for Microbiology, 1980:290.
29. Henderson DC, Rippin JJ. Stimulus-dependent production of cytokines and pterins by peripheral blood mononuclear cells. Immunol Lett. 1995;45:29-34.
30. Frost P, Ng CP, Belldegrun A, et al. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol. 1997;180:70-83.
31. Decoster E, Vanhaeesebroeck B, Vanderbeele P, et al. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J Biol Chem. 1995;270:18473-18478.
32. Liu AN, Mohammed AZ, Rice WR, et al. Perform-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Am J Respir Cell Mol Biol. 1999;20:849-858.
33. Verneris MR, Ito M, Baker J, et al. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001;7:532-542.
34. Doherty DG, Norris S, Estebas LM, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol. 1999;163:2314-2321.
35. Sun R, Fan J, Wei H, et al. Use of interleukin-15 for preparation of adherent NK cells from human peripheral blood: comparison with interleukin-2. J Immunol Methods. 2003;279:79-90.
36. Koller MD, Kiener HP, Aringer M, et al. Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency. Clin Exp Immunol. 2003;132:225-231.
37. Lin SJ, Roberts RL, Ank BJ, et al. Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. J Clin Immunol. 1998;18:335-345.
38. Alves NL, Hooibrink B, Arosa FA, et al. IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood. 2003;102:2541-2546.
39. Rutella S, Rumi C, Lucia MB, et al. Flow cytometric detection of perform in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. Immunol Lett. 1998;60:51-55.
40. Xian CL, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med. 2001;7:114-118.
41. Rutella S, Pierelli L, Bonanno G, et al. Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol. 2001;29:1503-1516.
42. Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99:937-943.
43. Hoontrakoon R, Chu HW, Gardai SJ, et al. Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via automne production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappaB activation. Am J Respir Cell Mol Biol. 2002;26:404-412.
44. Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA. 2000;97:11445-11450.
45. Ranson T, Vosshenrich CAJ, Corcuff E, et al. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc Natl Acad Sci USA. 2003;100:2663-2668.
46. Stremmel C, Exley M, Balk S, et al. Characterization of the phenotype and function of CD8(+), alpha/beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets. Eur J Immunol. 2001;31:2818-2828.
47. Lauwerys BR, Garot N, Renauld JC, et al. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165:1847-1853.
48. Street SEA, Cretney E, Smyth MJ. Perform and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood. 2001;97:192-197.